Roche

Top 5 pipeline drugs for 2018
Top 5 pipeline drugs for 2018New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.
New cancer biosimilar could net major sales
New cancer biosimilar could net major salesA new biosimilar to the cancer drug Herceptin, which raked in $2.5 billion in US sales last year, is expected to produce blockbuster sales in the US.
FDA approves generic Tamiflu, plus 2 other new drugs
FDA approves generic Tamiflu, plus 2 other new drugsFDA approved the first generic version of oseltamivir phosphate (Tamiflu, Roche) for oral suspension to treat influenza A and B, plus 2 other noteworthy therapies.
Lung cancer drug approvedSoon after FDA granted accelerated approval for atezolizumab (Tecentriq, Genentech) to treat bladder cancer, the agency okayed the drug to treat metastatic non-small cell lung cancer (NSCLC).
Giant cell arteritis treatment expeditedThe US Food and Drug Administration (FDA) is expediting its review of a new potential treatment for giant cell arteritis, a rare inflammatory disease that can cause permanent vision loss, Roche has announced.
What anti-PD-L1 immunotherapy approval means for urologyUrologist Peter Black, MD, discusses the recent FDA approval of atezolizumab (TECENTRIQ) for the most common form of bladder cancer as well as a complementary diagnostic test.
MS drugs make major advancementsThere is new hope for patients with multiple sclerosis (MS) after positive data on Gilenya and the investigational drug ocrelizumab was presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain.
Continued advances in cancer outcomes unveiled at ASCOLeading cancer drugs reduced the risk of death by half for people with lung cancer and assisted patients with HER2-positive breast cancer live longer without the disease recurring. The findings were just two of the numerous important study results presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago, Ill., this week.
FDA drug approvals-May 2015FDA actions in brief, complete response, breakthrough therapy designation, fast-track designations, orphan drug designations
Eylea far better for DME patients, NIH study reports
Eylea far better for DME patients, NIH study reportsAflibercept is reportedly superior to ranibizumab and bevacizumab when treating some patients with diabetic macular edema (DME), according to a National Institutes of Health (NIH)-sponsored clinical trial.